◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 0858

Extrawell Pharmaceutical Holdings Limited (0858) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-10

Extrawell Pharmaceutical Holdings Limited (0858) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Quarry Bay, Hong Kong with about 158 employees. Its market capitalization is roughly HKD 232 million. In the fiscal year ended 2025-03-31, 0858 reported HKD 55M in revenue and HKD 223M in net income.

Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sell of pharmaceutical products in the People's Republic of China and Hong Kong. It operates through Manufacturing and Trading segments.

Interactive charts & full statements →

0858 Revenue & Earnings History — Annual Income Statement

Income statement2025-03-312024-03-312023-03-312022-03-31
Total RevenueHKD 55MHKD 59MHKD 73MHKD 74M
Gross ProfitHKD 22MHKD 29MHKD 31MHKD 38M
Operating Income (EBIT)(HKD 9M)(HKD 6M)(HKD 12M)(HKD 12M)
Net IncomeHKD 223M(HKD 163M)HKD 129MHKD 131M

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

0858 Free Cash Flow History

0858 Balance Sheet History

Balance sheet2025-03-312024-03-312023-03-312022-03-31
Total AssetsHKD 1.5BHKD 1.3BHKD 1.4BHKD 1.3B
Total LiabilitiesHKD 192MHKD 175MHKD 163MHKD 152M

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 0858 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← 0857All “0-9” companies0859 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.